INVA
Innoviva, Inc. Health Care Pharmaceutical Preparations Russell 3000
$21.22Close
$1.6BMarket cap
$17.95 – $24.2452-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Earnings shrinking EPS −251% year on year
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 2.7%
price change
1mo
0.0%
price change
12-month return
up 18%
market up 11% ·
its own up 10%
F-score
6 / 9
Mixed
Altman Z
3.37
Low risk
P/E
5.8×
price / earnings
PEG
0.01
P/E / EPS growth
P/B
1.4×
price / book
Earnings yield
up 12.7%
EBIT / enterprise value
Cheaper than
91%
of the market · markedly cheap
Revenue growth
up 15%
year on year
EPS growth
down 251%
latest quarter
Sales growth
up 19%
latest quarter · +9 pts
ROE
up 29%
return on equity
Free cash margin
up 48%
$195.8M FCF
D/E
0.22
long-term debt / equity
Net debt / EBITDA
-1.8×
net cash
Interest cover
9.8×EBIT / interest
Piotroski tests
- profits not fully backed by cash
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- reduced long-term debt
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
2.2%
$0.47 a day · 2×ATR $20.27
RS
52 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 19.1% over the year, from 63m to 75m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $271.2M came with $196.9M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
- Gross margin narrowing Gross margin fell from 82.6% to 74.8%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+2% vs market2 sessions after results
Financials
- Gross 75%
- Net 66%
- Free cash 48%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $336.8M | $391.9M | $331.3M | $310.5M | $358.7M | $411.3M |
| Gross margin | — | — | — | 79% | 83% | 75% |
| Operating income | $321.1M | $375.1M | — | $113.9M | $166.9M | $163.7M |
| Net income | $293.8M | $368.8M | $220.3M | $179.7M | $23.4M | $271.2M |
| Net margin | 87% | 94% | 66% | 58% | 7% | 66% |
| Earnings per share | $2.59 | $3.91 | $2.31 | $2.07 | $0.32 | $3.20 |
| Free cash flow | $313.1M | $363.8M | $201.7M | $140.7M | $188.4M | $195.8M |
| Free cash margin | 93% | 93% | 61% | 45% | 53% | 48% |
| Cash | $246.5M | $201.5M | $291.0M | $193.5M | $305.0M | $550.9M |
| Long-term debt | $385.5M | $394.7M | $444.2M | $446.2M | $256.3M | $257.7M |
| Shareholders' equity | $539.9M | $414.7M | $565.8M | $675.0M | $691.2M | $1.2B |
| Shares outstanding | 101.39m | 69.57m | 69.19m | 63.31m | 62.66m | 74.64m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| May 18, 2026 | Director or officer change ↗ |
| May 6, 2026 | Results ↗ |
| May 4, 2026 | Shareholder vote ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| May 21, 2025 | Shareholder vote ↗ |
| May 7, 2025 | Results ↗ |
| Feb 26, 2025 | Results ↗ |
| Nov 6, 2024 | Results ↗ |
| Jul 31, 2024 | Results ↗ |